Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: methodological uncertainties

摘要

BackgroundTo assess uncertainty in regulatory decision-making for orphan medicinal products (OMP), a summary of the current basis for approval is required; a systematic grouping of medical conditions may be useful in summarizing information and issuing recommendations for practice.